Nicotinic Agonists

• 

  Subject Areas on Research

  • 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. 
  • A Pilot Trial Examining African American and White Responses to Algorithm-Guided Smoking Cessation Medication Selection in Persons Living with HIV. 
  • A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. 
  • A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. 
  • A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. 
  • A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. 
  • A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia. 
  • A ten fold reduction of nicotine yield in tobacco smoke does not spare the central cholinergic system in adolescent mice. 
  • A unique role for striatal serotonergic systems in the withdrawal from adolescent nicotine administration. 
  • AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. 
  • Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. 
  • Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. 
  • Adapting smoking cessation treatment according to initial response to precessation nicotine patch. 
  • Additive and synergistic effects of fetal nicotine and dexamethasone exposure on cholinergic synaptic function in adolescence and adulthood: Implications for the adverse consequences of maternal smoking and pharmacotherapy of preterm delivery. 
  • Administration of nicotine to adolescent rats evokes regionally selective upregulation of CNS alpha 7 nicotinic acetylcholine receptors. 
  • Adolescent nicotine administration alters serotonin receptors and cell signaling mediated through adenylyl cyclase. 
  • Adolescent nicotine exposure causes persistent upregulation of nicotinic cholinergic receptors in rat brain regions. 
  • Adolescent nicotine exposure produces immediate and long-term changes in CNS noradrenergic and dopaminergic function. 
  • Adolescent nicotine: deficits in immune function. 
  • Adolescent vs. adult-onset nicotine self-administration in male rats: duration of effect and differential nicotinic receptor correlates. 
  • Adolescents and adults differ in the immediate and long-term impact of nicotine administration and withdrawal on cardiac norepinephrine. 
  • Alpha7 nicotinic acetylcholine receptors targeted by cholinergic developmental neurotoxicants: nicotine and chlorpyrifos. 
  • Ameliorating the developmental neurotoxicity of chlorpyrifos: a mechanisms-based approach in PC12 cells. 
  • An animal model of adolescent nicotine exposure: effects on gene expression and macromolecular constituents in rat brain regions. 
  • Antidepressant effects of nicotine in an animal model of depression. 
  • Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats. 
  • Asthma exacerbation after administration of nicotine nasal spray for smoking cessation. 
  • Behavioral deficits during early stages of aging in Caenorhabditis elegans result from locomotory deficits possibly linked to muscle frailty. 
  • Changes in resting state functional brain connectivity and withdrawal symptoms are associated with acute electronic cigarette use. 
  • Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. 
  • Characterization of the facilitative effects of perinatal choline supplementation on timing and temporal memory. 
  • Cholinergic receptors in heart and brainstem of rats exposed to nicotine during development: implications for hypoxia tolerance and perinatal mortality. 
  • Cholinergic systems in brain development and disruption by neurotoxicants: nicotine, environmental tobacco smoke, organophosphates. 
  • Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: interactions with clozapine actions and attentional performance in rats. 
  • Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding. 
  • Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. 
  • Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. 
  • Co-expression of nAChRs and molecules of the bitter taste transduction pathway by epithelial cells of intrapulmonary airways. 
  • Cognitive and Behavioral Impairments Evoked by Low-Level Exposure to Tobacco Smoke Components: Comparison with Nicotine Alone. 
  • Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. 
  • Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm. 
  • Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. 
  • Combined exposure to nicotine and ethanol in adolescent mice differentially affects anxiety levels during exposure, short-term, and long-term withdrawal. 
  • Combined exposure to nicotine and ethanol in adolescent mice differentially affects memory and learning during exposure and withdrawal. 
  • Conditional expression in corticothalamic efferents reveals a developmental role for nicotinic acetylcholine receptors in modulation of passive avoidance behavior. 
  • Denicotinized cigarettes: a new tool to combat cigarette addiction? 
  • Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals. 
  • Development of nicotinic drug therapy for cognitive disorders. 
  • Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats. 
  • Differential efficacies of the nicotinic α4β2 desensitizing agents in reducing nicotine self-administration in female rats. 
  • Dissociating the nicotine and airway sensory effects of smoking. 
  • Do heavy smokers need a higher replacement dose of nicotine to quit? 
  • EEG, physiology, and task-related mood fail to resolve across 31 days of smoking abstinence: relations to depressive traits, nicotine exposure, and dependence. 
  • Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. 
  • Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. 
  • Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. 
  • Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. 
  • Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial-arm maze. 
  • Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys. 
  • Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. 
  • Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats. 
  • Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. 
  • Effects of varenicline and cognitive bias modification on neural response to smoking-related cues: study protocol for a randomized controlled study. 
  • Excitatory and inhibitory circuitry in the superficial gray layer of the superior colliculus. 
  • Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. 
  • Gain modulation by nicotine in macaque v1. 
  • Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. 
  • High affinity binding of [3H]epibatidine to rat brain membranes. 
  • IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs. 
  • Idazoxan blocks the nicotine-induced reversal of the memory impairment caused by the NMDA glutamate receptor antagonist dizocilpine. 
  • Impact of adolescent nicotine exposure on adenylyl cyclase-mediated cell signaling: enzyme induction, neurotransmitter-specific effects, regional selectivities, and the role of withdrawal. 
  • Individual differences in novelty-seeking behavior but not in anxiety response to a new environment can predict nicotine consumption in adolescent C57BL/6 mice. 
  • Induction of tyrosine hydroxylase in the locus coeruleus of transgenic mice in response to stress or nicotine treatment: lack of activation of tyrosine hydroxylase promoter activity. 
  • Interaction of nicotinic and histamine H(3) systems in the radial-arm maze repeated acquisition task. 
  • Ketanserin attenuates nicotine-induced working memory improvement in rats. 
  • Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats. 
  • Lasting effects of nicotine treatment and withdrawal on serotonergic systems and cell signaling in rat brain regions: separate or sequential exposure during fetal development and adulthood. 
  • Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial. 
  • Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. 
  • Loss of neonatal hypoxia tolerance after prenatal nicotine exposure: implications for sudden infant death syndrome. 
  • Maternal exposure of rats to nicotine via infusion during gestation produces neurobehavioral deficits and elevated expression of glial fibrillary acidic protein in the cerebellum and CA1 subfield in the offspring at puberty. 
  • Maternal exposure to nicotine and chlorpyrifos, alone and in combination, leads to persistently elevated expression of glial fibrillary acidic protein in the cerebellum of the offspring in late puberty. 
  • Mecamylamine acutely increases human intravenous nicotine self-administration. 
  • Menthol decreases oral nicotine aversion in C57BL/6 mice through a TRPM8-dependent mechanism. 
  • Metallothionein expression and neurocognitive function in mice. 
  • Mimicking maternal smoking and pharmacotherapy of preterm labor: fetal nicotine exposure enhances the effect of late gestational dexamethasone treatment on noradrenergic circuits. 
  • Mode of action: disruption of brain cell replication, second messenger, and neurotransmitter systems during development leading to cognitive dysfunction--developmental neurotoxicity of nicotine. 
  • Molecular genetics of successful smoking cessation: convergent genome-wide association study results. 
  • Negative affect subtypes and craving differentially predict long-term cessation success among smokers achieving initial abstinence. 
  • Neonatal 6-hydroxydopamine lesions of the frontal cortex in rats: persisting effects on locomotor activity, learning and nicotine self-administration. 
  • Neuro-anatomic mapping of dopamine D1 receptor involvement in nicotine self-administration in rats. 
  • Neuroanatomical circuitry mediating the sensory impact of nicotine in the central nervous system. 
  • Neurobehavioral impairments caused by developmental imidacloprid exposure in zebrafish. 
  • Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch. 
  • Nicotine administration in adolescence reprograms the subsequent response to nicotine treatment and withdrawal in adulthood: sex-selective effects on cerebrocortical serotonergic function. 
  • Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade. 
  • Nicotine and clozapine effects on attentional performance impaired by the NMDA antagonist dizocilpine in female rats. 
  • Nicotine and non-nicotine smoking factors differentially modulate craving, withdrawal and cerebral blood flow as measured with arterial spin labeling. 
  • Nicotine effects on learning in zebrafish: the role of dopaminergic systems. 
  • Nicotine enhances stimulus detection performance of middle- and old-aged rats: a longitudinal study. 
  • Nicotine exposure in adolescence alters the response of serotonin systems to nicotine administered subsequently in adulthood. 
  • Nicotine for postoperative analgesia: a systematic review and meta-analysis. 
  • Nicotine increases anterior insula activation to expected and unexpected outcomes among nonsmokers. 
  • Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. 
  • Nicotine increases size and severity of experimental choroidal neovascularization. 
  • Nicotine inhibits voltage-dependent sodium channels and sensitizes vanilloid receptors. 
  • Nicotine is a developmental neurotoxicant and neuroprotectant: stage-selective inhibition of DNA synthesis coincident with shielding from effects of chlorpyrifos. 
  • Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. 
  • Nicotine preloading: the importance of a pre-cessation reduction in smoking behavior. 
  • Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. 
  • Nicotine therapy in adulthood reverses the synaptic and behavioral deficits elicited by prenatal exposure to phenobarbital. 
  • Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. 
  • Nicotine-alcohol interactions and cognitive function in rats. 
  • Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. 
  • Nicotine-haloperidol interactions and cognitive performance in schizophrenics. 
  • Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. 
  • Nicotinic acetylcholine involvement in cognitive function in animals. 
  • Nicotinic acetylcholine receptor stimulation impairs epidermal permeability barrier function and recovery and modulates cornified envelope proteins. 
  • Nicotinic alpha7- or beta2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. 
  • Nicotinic antagonist effects in the mediodorsal thalamic nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive function. 
  • Nicotinic attention-deficit/hyperactivity disorder treatment. 
  • Nicotinic involvement in memory function in zebrafish. 
  • Nicotinic receptor subtypes and cognitive function. 
  • Nicotinic receptors in the habenula: importance for memory. 
  • Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. 
  • Nicotinic treatment for cognitive dysfunction. 
  • Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. 
  • Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: effects on spatial working memory in rats. 
  • Nicotinic-glutamatergic interactions and attentional performance on an operant visual signal detection task in female rats. 
  • Novel insights for systemic inflammation in sepsis and hemorrhage. 
  • Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function. 
  • Oral sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, reduces nicotine self-administration in rats. 
  • Outcomes from an outpatient smoking-cessation clinic. 
  • Permanent, sex-selective effects of prenatal or adolescent nicotine exposure, separately or sequentially, in rat brain regions: indices of cholinergic and serotonergic synaptic function, cell signaling, and neural cell number and size at 6 months of age. 
  • Pharmacologic and sensorimotor components of satiation in cigarette smoking. 
  • Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. 
  • Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field. 
  • Prenatal nicotine alters the developmental neurotoxicity of postnatal chlorpyrifos directed toward cholinergic systems: better, worse, or just "different?". 
  • Prenatal nicotine effects on memory in rats: pharmacological and behavioral challenges. 
  • Prenatal nicotine exposure alters the response to nicotine administration in adolescence: effects on cholinergic systems during exposure and withdrawal. 
  • Prenatal nicotine exposure alters the responses to subsequent nicotine administration and withdrawal in adolescence: Serotonin receptors and cell signaling. 
  • Prenatal nicotine exposure evokes alterations of cell structure in hippocampus and somatosensory cortex. 
  • Public health clinical demonstration project for smoking cessation in american veterans who served since september 11, 2001. 
  • Randomized trial comparing mindfulness training for smokers to a matched control. 
  • Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. 
  • Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. 
  • Reduction of nicotine self-administration by chronic nicotine infusion with H1 histamine blockade in female rats. 
  • Regional brain activity correlates of nicotine dependence. 
  • Resolving postoperative neuroinflammation and cognitive decline. 
  • Response to Gorelick. 
  • Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. 
  • Role of insular cortex D₁ and D₂ dopamine receptors in nicotine self-administration in rats. 
  • Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. 
  • Scientific and clinical challenges in sepsis. 
  • Silver acetate interactions with nicotine and non-nicotine smoke components. 
  • Smoking and ischemic stroke: a role for nicotine? 
  • Teratogenic, bioenergetic, and behavioral effects of exposure to total particulate matter on early development of zebrafish (Danio rerio) are not mimicked by nicotine. 
  • The Effects of Nicotine and Tobacco Use on Brain Reward Function: Interaction With Nicotine Dependence Severity. 
  • The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. 
  • The anti-inflammatory potential of selective cholinergic agonists. 
  • The effect of nicotine and trauma context on acoustic startle in smokers with and without posttraumatic stress disorder. 
  • The importance of nicotinic acetylcholine receptors in schizophrenia, bipolar disorder and Tourette's syndrome. 
  • The neuronal strategy for inflammation. 
  • The role of alpha7 and alpha4beta2 nicotinic receptors in the nicotine-induced anxiolytic effect in zebrafish. 
  • The vagus nerve and the nicotinic anti-inflammatory pathway. 
  • Time-dependent changes in nicotine behavioral responsivity during early withdrawal from chronic cocaine administration and attenuation of cocaine sensitization by mecamylamine. 
  • Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. 
  • Transdermal nicotine for analgesia after radical retropubic prostatectomy. 
  • Twenty-first century tobacco use: it is not just a risk factor anymore. 
  • Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. 
  • Varenicline effects on craving, cue reactivity, and smoking reward. 
  • Varenicline-induced drug eruption with resulting palmar/plantar hyperhidrosis and dysesthesia. 
  • Ventral hippocampal alpha 7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze. 
  • Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. 
  • Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats. 
  • Ventral hippocampal ibotenic acid lesions block chronic nicotine-induced spatial working memory improvement in rats. 
  • Zebrafish assessment of cognitive improvement and anxiolysis: filling the gap between in vitro and rodent models for drug development. 
  • Zebrafish provide a sensitive model of persisting neurobehavioral effects of developmental chlorpyrifos exposure: comparison with nicotine and pilocarpine effects and relationship to dopamine deficits. 
  • beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. 
  • α4β2 Nicotinic receptor desensitizing compounds can decrease self-administration of cocaine and methamphetamine in rats. 
• 

  Keywords of People

  • Acheson, Shawn K., Assistant Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Translational Neuroscience